COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

Search Clinical Trials

Clinical Trials Sub Category

Clinical Trials Condition

All of Us Research Program

Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.

227 results

Alector (FTD)

This project is being done to determine if the experimental drug AL001 is effective and safe in treating individuals who have a known progranulin gene mutation that causes FTD, when compared to placebo (a solution that contains no active AL001 drug).

General Eligibility

  • Known pre-symptomatic or symptomatic carriers of a heterozygous loss-of-function GRN mutation causative of FTD
  • 18 – 85 years old
  • Suitable study partner

PLEASE consult Dr. Granadillo to send patient for genetic counseling and testing for the GRN mutation. This is for clinical purposes and not part of the research ...

Sub Category
Alzheimer's & Dementia

ADvance II (probable AD mild)

The ADvance II Study is researching the use of deep brain stimulation of the fornix (known as DBS-f), a place in the brain that plays a central role in memory, in people with Alzheimer’s disease. 

DBS-f uses a surgically implanted medical device, similar to a heart pacemaker, to deliver mild electrical pulses to precisely targeted areas of the brain.

General Eligibility

  • At least 65 years old with Probable Alzheimer’s disease mild
  • Has an available caregiver or other appropriate knowledgeable informant
  • Must be a good surgical candidate for placement of a deep brain stimulator
  • Eit ...
Sub Category
Alzheimer's & Dementia

Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors

This study is being done for the following purposes:
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
Protocol No
TRISHULA-TTX-030-002
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers, Prostate and Urologic Cancers, Head and Neck Cancers

A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer

The purpose of this study is to evaluate in patients with metastatic pancreatic cancer, the overall safety, tolerability, and preliminary anti-tumor activity of adding an investigational drug, L DOS47, to doxorubicin, a type of chemotherapy drug
Protocol No
HELIX-LDOS006
Sub Category
Gastrointestinal Cancers, Early Phase/Multiple Disease Site Cancers

A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

Phase 3 Study of Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in mCRPC
Protocol No
MERCK-MK-7339-010
Sub Category
Prostate and Urologic Cancers

A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors

Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Protocol No
ALLIANCE-A031102
Sub Category
Prostate and Urologic Cancers

A Phase I, Open-Label, Multicenter, Study of WVT078 in Subjects with Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to find the best dose of WVT078 or WVT078 combined with WHG626 that can be given to patients with multiple myeloma and to evaluate how well the treatment might work in treating patients with this type of cancer. This is the first time WVT078 or WVT078 combined with WHG626 are being used in humans. WHG626 has been studied previously in patients with different types of cancer than yours
Protocol No
NOVARTIS-CWVT078A12101
Sub Category
Early Phase/Multiple Disease Site Cancers

A Phase 1b Trial of Magrolimab Monotherapy Or Magrolimab In Combination With Azacitidine In Patients With Hematological Malignancies

The purpose of this study is to test the safety of Hu5F9-G4 alone, or in combination with azacitidine in patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Other purposes of this study are to determine the best dose of Hu5F9-G4, the quantity of Hu5F9-G4 in your blood, the side effects it has on your body, and whether or not it can improve your cancer.
Protocol No
FORTYSEVEN-5F9005
Sub Category
Early Phase/Multiple Disease Site Cancers